GET DAILY SIGNALSWhy Is Nanobiotix (NBTX) Stock Up +13.85% Today?
Key Takeaways
- NBTX shares climbed 13.85% to $24.00, up from the prior session's close of $21.08.
- The advance marks a sharp rebound after the stock fell roughly 32% over the preceding month, leaving it deeply oversold.
- No single company-specific headline drove the session; the move reflects an oversold technical bounce and bargain hunting.
- A supportive fundamental backdrop — the Johnson & Johnson partnership, encouraging clinical data, and a cash runway into 2029 — underpinned buying interest.
- Traders are watching upcoming clinical readouts, including final Phase 3 NANORAY-312 data expected in the first half of 2027.
Opening Summary
Nanobiotix S.A. (NBTX), a Paris-based late-stage clinical biotechnology company pioneering physics-based nanotherapeutics for cancer, saw its American Depositary Shares surge in today's session. The stock traded up 13.85% to $24.00, compared with a prior closing price of $21.08, confirming a decisive move higher. The rally followed a steep, month-long selloff that had pushed shares into deeply oversold territory, prompting a wave of bargain hunting and technical buying rather than any single discrete announcement.
An Oversold Technical Rebound
The most immediate driver of today's advance appears to be technical rather than fundamental. NBTX had shed approximately 32% over the prior month, erasing much of the earlier 2026 gains and leaving its relative strength index (RSI) near the low-20s — a level widely viewed as oversold. After several sessions of declining volume and drifting prices, buyers stepped in, sparking a sharp intraday recovery that lifted shares well off their recent lows.
This pattern of a violent bounce following an extended decline is common among small- and mid-cap biotechnology names, where thinner trading volumes can amplify price swings in both directions. Today's move partially retraced the prior month's losses even as the stock remained below its longer-term moving averages, indicating the recovery is still in its early stages from a technical standpoint.
A Supportive Fundamental Backdrop
Beyond the technical setup, the rebound drew support from the company's underlying fundamentals. NBTX is advancing its lead radio-enhancer, NBTXR3 (also known as JNJ-1900), in partnership with Johnson & Johnson (JNJ). The drug candidate, a suspension of hafnium oxide nanoparticles injected directly into tumors before radiotherapy, has generated encouraging data across multiple solid-tumor indications, including head and neck cancer and non-small cell lung cancer.
Recent clinical updates have reinforced the program's potential. Data presented in 2026 highlighted high overall response rates and a deepening of responses over time in Stage 3 non-small cell lung cancer, alongside a favorable safety profile. Meanwhile, the pivotal Phase 3 NANORAY-312 study in head and neck cancer remains on track, with final results anticipated in the first half of 2027.
Financially, the company reported cash and cash equivalents of approximately €110.9 million as of mid-2026, following a follow-on offering completed in May. Management has indicated this provides a runway to fund operations into 2029, a factor that reduces near-term dilution and financing risk and may have encouraged investors to treat the sharp pullback as a buying opportunity.
Broader Sector and Sentiment Context
The move also unfolded within a broader environment where biotechnology and oncology-focused names have seen selective buying interest, particularly those with late-stage catalysts and large-market opportunities. Analysts have been constructive on the stock, with Guggenheim initiating coverage in September with a Buy rating and a price objective of $64, citing the radio-enhancer platform's multi-billion-dollar addressable market across head and neck and lung cancers.
Market Context and Trading Activity
The advance came after a period of lighter-than-average trading volume, and the rebound itself reflected renewed buying interest following the extended downtrend. While the stock remains below its 50-day and 200-day moving averages, today's move reclaimed a portion of the lost ground and signaled a potential shift in near-term momentum. The rally was more pronounced than typical daily swings for NBTX, underscoring the volatility characteristic of clinical-stage biotech equities with upcoming binary catalysts.
What Comes Next for NBTX
Looking ahead, the primary catalysts for NBTX are clinical and regulatory. Investors will focus on continued data updates from the Johnson & Johnson-led CONVERGE Phase 2 study in unresectable Stage 3 non-small cell lung cancer and on the final readout from the Phase 3 NANORAY-312 trial in head and neck cancer expected in the first half of 2027. Additional data readouts and partnership milestones could further influence sentiment.
Risks remain material. The company is not yet profitable, its revenue is limited, and its valuation rests heavily on the clinical success of a single lead asset. Sustaining today's rebound will likely depend on follow-through buying, constructive biotech sector conditions, and continued execution across its pipeline and partnership programs.
Trending AI Robots
For traders seeking a systematic edge, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing AI trading bots. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, yet only those demonstrating the strongest performance under current market conditions are featured in this dedicated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols. Explore the Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NBTX's Stochastic Oscillator is sitting in oversold zone for 15 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 192 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NBTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for NBTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-32.154) is normal, around the industry mean (2.978). P/E Ratio (-19.339) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement